In a decisive move to curb a burgeoning public health crisis, the Coalition for Epidemic Preparedness Innovations (CEPI) has announced a strategic, high-speed initiative to accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus (BDBV). The virus, currently circulating in the Democratic Republic of the Congo (DRC) and Uganda, represents a significant threat to regional stability, with no currently licensed vaccines or established clinical development pipelines to combat it.
Following an exhaustive global review and extensive consultations with the World Health Organization (WHO), the Africa Centres for Disease Control and Prevention (Africa CDC), and a network of international health experts, CEPI has selected candidates from IAVI, Moderna, and the University of Oxford. This tripartite approach is designed to diversify the technological arsenal available to clinicians, leveraging proven platforms that have previously demonstrated success against other filoviruses.
The Urgent Need: A Rare but Deadly Pathogen
The Bundibugyo ebolavirus is a member of the Ebolavirus genus, known for causing severe hemorrhagic fever in humans. While there have only been two documented outbreaks of this specific strain in history, the current surge in the DRC and Uganda has underscored the dangerous lack of medical countermeasures. Unlike the Zaire ebolavirus, for which several vaccines exist, the BDBV remains an "orphan" pathogen in terms of pharmaceutical development—a reality that Richard Hatchett, CEO of CEPI, labeled an unacceptable vulnerability.
"With the Bundibugyo virus spreading rapidly and no licensed vaccines currently available, every day counts in the race against this deadly disease," Hatchett stated in a recent press briefing. "CEPI’s urgent funding and support for these three promising candidates aim to advance safe, effective vaccines to help control this epidemic and build long-term regional security."
Chronology: From Outbreak to Accelerated Action
The timeline for this intervention has been compressed to meet the exigencies of the current outbreak.
- Initial Detection: Health authorities in the DRC and Uganda identified a cluster of cases exhibiting symptoms consistent with filovirus infection. Genomic sequencing confirmed the presence of the BDBV strain.
- Global Review: Recognizing the lack of existing countermeasures, CEPI initiated a rapid call for proposals and a consultative review process involving the WHO and Africa CDC.
- Candidate Selection: Within weeks, the three platforms—rVSV (IAVI), mRNA (Moderna), and ChAdOx1 (Oxford)—were identified as the most viable candidates based on technological maturity and speed of scalability.
- Funding Mobilization: CEPI finalized initial grant agreements for all three entities, focusing on the immediate generation of Master Virus Seed stocks and the initiation of GMP (Good Manufacturing Practice) production processes.
- Current Status: As of mid-2026, the programs are in the pre-clinical and early-development phases, with clinical trial protocols being finalized in collaboration with local health ministries in the affected regions.
Technological Pillars: The Three Vaccine Strategies
1. IAVI’s rVSV Platform
IAVI’s candidate, which originated from research at The University of Texas Medical Branch, employs a recombinant vesicular stomatitis virus (rVSV) vector. This technology is widely considered the "gold standard" for filovirus prevention, as it forms the basis of the only licensed vaccine for the Zaire ebolavirus and was successfully deployed during the 2025 Sudan virus outbreak in Uganda.
The candidate is designed to elicit robust protective immunity after a single dose. While preclinical studies in non-human primates have shown high levels of efficacy, the vaccine has not yet undergone human clinical trials. CEPI has allocated $3.2 million to facilitate the generation of a Master Virus Seed stock and to transition the manufacturing process to a contract development and manufacturing organization (CDMO).
2. Moderna’s mRNA Innovation
Moderna’s involvement marks a significant investment in mRNA technology for rare disease outbreaks. CEPI has pledged up to $50 million for this candidate, covering the full spectrum of preclinical testing, Phase 1 trials, and concurrent manufacturing. This "at-risk" manufacturing strategy is intended to ensure that, should Phase 1 data prove positive, the program can seamlessly transition into Phase 2 and 3 trials without the typical production bottlenecks.
Stephane Bancel, CEO of Moderna, emphasized the commitment to this effort: "We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
3. The University of Oxford’s ChAdOx1 Vector
The University of Oxford is utilizing its ChAdOx1 viral vector platform—the same technology that underpinned the AstraZeneca COVID-19 vaccine. This platform has shown high versatility, having been previously adapted to target related filoviruses, including the Sudan virus and the Marburg virus. CEPI has invested $8.6 million into this program to cover preclinical testing and the production of clinical-grade doses, aiming to capitalize on the platform’s known safety profile and established manufacturing pathways.
Financial Context and Market Implications
The financial landscape for these projects is complex. For Moderna, this partnership arrives during a period of fiscal transition. Following a 30% year-over-year revenue decline in the fourth quarter of 2025 and a challenging start to 2026, the company is pivoting its R&D focus. With $3.1 billion spent on research in 2025 against only $1.9 billion in revenue, the CEPI grant serves as a critical de-risking mechanism.
For a commercially viable pharmaceutical company, investing in a vaccine for a rare, localized strain of Ebola is often deemed a "commercially risky" endeavor. By offloading these costs to CEPI, Moderna is able to continue refining its mRNA platform and gathering valuable clinical data on filoviruses without the burden of immediate commercial return.
This development is particularly notable given the current shift in U.S. federal policy. While CEPI is scaling up investment in mRNA, the U.S. government has significantly retracted its involvement in similar research. The termination of 22 mRNA-focused federal contracts in August 2025 suggests a move away from state-funded biotechnology in favor of private-public partnerships like the one facilitated by CEPI.
Implications for Global Health Security
The fast-tracking of these vaccines carries profound implications for global health equity and pandemic preparedness. By coordinating with organizations such as Gavi, the World Bank, and various development finance institutions, CEPI is not merely funding research; it is building a framework for "surge financing." This ensures that if any of the three candidates prove successful, the funding for large-scale procurement and distribution will already be in place, preventing the "vaccine nationalism" that hampered responses to previous pandemics.
Furthermore, the focus on multiple platforms—rVSV, mRNA, and viral vectors—provides a "hedge" against failure. If one technology fails to demonstrate safety or efficacy in humans, the remaining two act as a fail-safe.
Looking Ahead: The Future of Filovirus Defense
As the work on these candidates accelerates, CEPI continues to keep its doors open to other innovations. An open call for proposals remains active, signaling the organization’s intent to maintain a "living" pipeline of potential countermeasures.
The success of this initiative will be measured not only by the laboratory results but by the ability to deliver these vaccines to the frontlines of the DRC and Uganda. As Richard Hatchett noted, the ultimate goal is to move beyond reactionary measures and toward a proactive state of readiness, where the infrastructure for rapid deployment is as sophisticated as the science behind the vaccines themselves.
In a world increasingly prone to zoonotic spillovers, the BDBV response may well serve as a blueprint for how international health bodies can bridge the gap between initial outbreak detection and the delivery of life-saving medical technology. The next six to twelve months will be pivotal, as the world watches whether this bold, multi-pronged investment can turn the tide on the current epidemic and provide a lasting shield against future filovirus threats.
About the Author
